SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today an… […]
CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,… […]
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today an… […]
SAN DIEGO, Sept. 29, 2020 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colore… […]
SAN DIEGO, Aug. 21, 2020 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the closing of its previously … […]
SAN DIEGO, Aug. 18, 2020 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial pub… […]
CARLSBAD, Calif., Aug. 4, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, wit… […]
CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $1… […]
CARLSBAD, Calif., July 10, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, wi… […]
SAN DIEGO, July 9, 2020 /PRNewswire/ — Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the ca… […]
Copyright © 2021 Biotech Networks, LLC
